Laurus labs inks pact with IIT Kanpur

19 Jun 2023 Evaluate

Laurus labs has signed a Memorandum of Agreement (MOA) with IIT Kanpur (IITK) to bring novel gene therapy assets to market. As per MOA, Laurus labs will in-license few gene therapy assets and will provide research grant for advancing these products through the pre-clinical development. The company will also provide funding for the clinical trials and will launch these products in India and emerging markets. Additionally, The company will establish a GMP facility at the Techno Park facility of IITK.

Department of Biological Sciences and Bioengineering (BSBE) at IIT Kanpur has been working on gene therapy for the last few years and have developed few gene therapy assets along with technology for novel Adeno Associated Virus (AAV) vectors. They have filed IPs around these products and few additional patent applications will be filed in due course.

This partnership allows Laurus Labs to strengthen its presence in the promising Cell and Gene Therapy (CGT) space and allows it to become a leader in this space. These therapies are not available in India and emerging markets and this collaboration will help it in bringing these novel therapies to Indian patients at an affordable pricing. Additionally, this allows Laurus labs to offer CDMO services to cell and gene therapy companies.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

551.45 7.90 (1.45%)
28-Nov-2024 16:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.15
Dr. Reddys Lab 1192.65
Cipla 1498.65
Lupin 2000.00
Zydus Lifesciences 949.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.